Endometriosis diagnosis is often delayed due to the need for invasive surgical procedures, leading to prolonged suffering and delayed treatment for affected individuals. Current diagnostic methods lack the sensitivity and accessibility needed for early and widespread screening.

EndoGene.Bio is developing non-invasive diagnostic tests for endometriosis utilizing epigenetic markers detectable in menstrual blood samples. This approach aims to provide a more accessible and reliable method for early detection, reducing the time to diagnosis and enabling earlier intervention. By analyzing specific epigenetic signatures, the test can identify the presence of endometriosis without the need for surgery. The company's focus is on improving patient outcomes through timely and accurate diagnosis.

Analysis of epigenetic markers in menstrual blood samples

Non-invasive diagnostic approach, eliminating the need for surgical procedures

Early detection of endometriosis, enabling timely intervention

Identification of specific epigenetic signatures associated with endometriosis

The primary target audience includes women experiencing symptoms suggestive of endometriosis, as well as gynecologists and other healthcare providers seeking improved diagnostic tools for this condition.